

William E Brady

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11248248/publications.pdf>

Version: 2024-02-01

22
papers

1,727
citations

393982

19
h-index

676716

22
g-index

22
all docs

22
docs citations

22
times ranked

2123
citing authors

#	ARTICLE	IF	CITATIONS
1	Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG) Tj ETQq1 1 0.784314 rgBT /Overbo 541-553.	6.3	75
2	Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study. Gynecologic Oncology, 2020, 158, 562-569.	0.6	35
3	Clinical trial methodology in rare gynecologic tumor research: Strategies for success. Gynecologic Oncology, 2018, 149, 605-611.	0.6	8
4	A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology, 2018, 151, 202-207.	0.6	10
5	Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001). Gynecologic Oncology, 2018, 150, 9-13.	0.6	44
6	Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?. Gynecologic Oncology, 2018, 150, 253-260.	0.6	21
7	A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 147, 283-290.	0.6	37
8	An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecologic Oncology, 2017, 147, 243-249.	0.6	61
9	Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy. Clinical Cancer Research, 2017, 23, 1955-1966.	3.2	27
10	Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the <scp>M</scp>alignant <scp>G</scp>erm <scp>C</scp>ell <scp>T</scp>umor <scp>I</scp>nternational <scp>C</scp>ollaborative. Cancer, 2016, 122, 230-237.	2.0	91
11	A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2016, 140, 204-209.	0.6	40
12	A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group study. Gynecologic Oncology, 2014, 133, 537-541.	0.6	31
13	Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncology, The, 2013, 14, 134-140.	5.1	322
14	Effectiveness of Ezetimibe Added to Ongoing Statin Therapy in Modifying Lipid Profiles and Low-Density Lipoprotein Cholesterol Goal Attainment in Patients of Different Races and Ethnicities: A Substudy of the Ezetimibe Add-On to Statin for Effectiveness Trial. Mayo Clinic Proceedings, 2006, 81, 1177-1185.	1.4	28
15	Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diabetes and Vascular Disease Research, 2006, 3, 93-102.	0.9	65
16	Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Current Medical Research and Opinion, 2006, 22, 2041-2053.	0.9	101
17	A Community-Based, Randomized Trial of Ezetimibe Added to Statin Therapy to Attain NCEP ATP III Goals for LDL Cholesterol in Hypercholesterolemic Patients: The Ezetimibe Add-On to Statin for Effectiveness (EASE) Trial. Mayo Clinic Proceedings, 2005, 80, 587-595.	1.4	241
18	Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Current Medical Research and Opinion, 2005, 21, 1123-1130.	0.9	42

#	ARTICLE	IF	CITATIONS
19	LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD. MedGenMed: Medscape General Medicine, 2005, 7, 3.	0.2	3
20	Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. American Journal of Cardiology, 2004, 93, 1487-1494.	0.7	184
21	Human Serum Carotenoid Concentrations Are Related to Physiologic and Lifestyle Factors. Journal of Nutrition, 1996, 126, 129-137.	1.3	210
22	Influence of Using Different Sources of Carotenoid Data in Epidemiologic Studies. Journal of the American Dietetic Association, 1996, 96, 1271-1275.	1.3	51